Fort Worth, Texas
2017 revenues: $6,024,000,000
2017 R&D spend: $490,000,000
Fiscal year ending: December 31, 2017
Mike Ball, chairman; David Endicott, CEO; Kim Adler, VP, global communications head; Larent Attias, SVP, corporate development strategy; Royce Edward, SVP, GC; Ian Bell, president, EMEA; Sergio Duplan, president, NA; Camilia Finzi, president, Latin America & the Caribbean; Franck Leveiller, head, global R&D; Sue-Jean Lin, SVP, CIO; Merrick McCracken, SVP, HR; Ed McGough, SVP, global manufacturing & technical operations; Jim Murphy, president, Japan; David Murray, CFO; Rajkumar Narayanan, president, Asia; Michael Onuscheck, head, Alcon Surgical; Andy Pawson, president & GM, global vision care franchise; Dave Schoening, SVP quality; Eric van Oppens, head, global strategic initiatives
Novartis said in June that it’s planning to spin the device portions of its Alcon ophthalmology subsidiary into a publicly traded company after years of underperformance, retaining Alcon’s $4.6 billion ophthalmic pharmaceuticals business. The spinoff, expected to close during the first half of 2019, is projected to create a $7 billion enterprise with more than 20,000 employees.